Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Netherlands,Australia,France,Russian Federation,United Kingdom,Switzerland,Belgium,Germany,Sweden,Spain
nct
MAJ Il y a 5 ans
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.
Pays
Australia
,
Austria
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Lebanon
,
Lithuania
,
Netherlands
,
Russian Federation
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Pays
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1